Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study
Introduction Life expectancy of patients with psoriasis is reduced by 4–5 years due to cardiovascular disease with an increased risk of myocardial infarction at an earlier age compared with the general population. This increased risk is independent of traditional cardiovascular risk factors and high...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/9/e072455.full |
| _version_ | 1797650755716382720 |
|---|---|
| author | Leticia Fernandez-Friera Jorge Solis Joel M Gelfand Carlota Abbad-Jaime de Aragón Emilio Berna-Rico María Asunción Ballester-Martinez Pedro Jaén Nehal N Mehta Álvaro González-Cantero María G Barderas |
| author_facet | Leticia Fernandez-Friera Jorge Solis Joel M Gelfand Carlota Abbad-Jaime de Aragón Emilio Berna-Rico María Asunción Ballester-Martinez Pedro Jaén Nehal N Mehta Álvaro González-Cantero María G Barderas |
| author_sort | Leticia Fernandez-Friera |
| collection | DOAJ |
| description | Introduction Life expectancy of patients with psoriasis is reduced by 4–5 years due to cardiovascular disease with an increased risk of myocardial infarction at an earlier age compared with the general population. This increased risk is independent of traditional cardiovascular risk factors and higher in moderate-to-severe forms of psoriasis. Inflammation may play a key role in the development of atherosclerosis in these patients.Methods and analysis A prospective cohort study, Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP), was initiated in January 2020 to investigate the presence and progression of subclinical atherosclerosis in patients with psoriasis. 120 patients aged 30–65 years and eligible for biological treatment have been recruited at Hospital Ramón y Cajal in Madrid, Spain. Patients undergo a baseline visit, and 1-year follow-up visit after starting biological therapy. Each visit includes: assessment of cardiovascular risk factors, screening for subclinical atherosclerosis by two-dimensional/three-dimensional ultrasound of carotid and femoral arteries, cardiac CT of coronary arteries and blood sampling. All baseline visits were completed by December 2022, and the remaining follow-up visits will be concluded by the end of 2023. The EDSAP study aims to identify new molecular and imaging markers associated with the presence of atherosclerosis and its progression in a chronic inflammatory state such as psoriasis. This has the potential to: (1) help improve primary cardiovascular prevention strategies in these patients; (2) understand the effect of biological drugs on the cardiovascular system; and (3) serve as a model for understanding atherosclerosis in other chronic inflammatory diseases.Ethics and dissemination The study protocol has been approved by the Institutional Review Board of the Hospital Ramón y Cajal in Madrid. We will present our findings at national and international congresses, and peer-reviewed journals.Trial Registration number NCT05858099. |
| first_indexed | 2024-03-11T16:06:02Z |
| format | Article |
| id | doaj.art-5b02c8156c504e24a8d19be98785b887 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-03-11T16:06:02Z |
| publishDate | 2023-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-5b02c8156c504e24a8d19be98785b8872023-10-25T02:15:07ZengBMJ Publishing GroupBMJ Open2044-60552023-09-0113910.1136/bmjopen-2023-072455Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort studyLeticia Fernandez-Friera0Jorge Solis1Joel M Gelfand2Carlota Abbad-Jaime de Aragón3Emilio Berna-Rico4María Asunción Ballester-Martinez5Pedro Jaén6Nehal N Mehta7Álvaro González-Cantero8María G Barderas9Cardiology, Atria Clinic, Madrid, SpainCardiology, Hospital Universitario 12 de Octubre, Madrid, SpainDermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USADermatology, Hospital Universitario Ramon y Cajal, Madrid, SpainDermatology, Hospital Universitario Ramon y Cajal, Madrid, SpainDermatology, Hospital Universitario Ramon y Cajal, Madrid, SpainDermatology, Hospital Universitario Ramon y Cajal, Madrid, SpainCardiology, George Washington Medical Center, Washington, DC, USADermatology, Hospital Universitario Ramon y Cajal, Madrid, SpainVascular Physiopathology, Hospital Nacional de Parapléjicos, IDISCAM, Toledo, SpainIntroduction Life expectancy of patients with psoriasis is reduced by 4–5 years due to cardiovascular disease with an increased risk of myocardial infarction at an earlier age compared with the general population. This increased risk is independent of traditional cardiovascular risk factors and higher in moderate-to-severe forms of psoriasis. Inflammation may play a key role in the development of atherosclerosis in these patients.Methods and analysis A prospective cohort study, Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP), was initiated in January 2020 to investigate the presence and progression of subclinical atherosclerosis in patients with psoriasis. 120 patients aged 30–65 years and eligible for biological treatment have been recruited at Hospital Ramón y Cajal in Madrid, Spain. Patients undergo a baseline visit, and 1-year follow-up visit after starting biological therapy. Each visit includes: assessment of cardiovascular risk factors, screening for subclinical atherosclerosis by two-dimensional/three-dimensional ultrasound of carotid and femoral arteries, cardiac CT of coronary arteries and blood sampling. All baseline visits were completed by December 2022, and the remaining follow-up visits will be concluded by the end of 2023. The EDSAP study aims to identify new molecular and imaging markers associated with the presence of atherosclerosis and its progression in a chronic inflammatory state such as psoriasis. This has the potential to: (1) help improve primary cardiovascular prevention strategies in these patients; (2) understand the effect of biological drugs on the cardiovascular system; and (3) serve as a model for understanding atherosclerosis in other chronic inflammatory diseases.Ethics and dissemination The study protocol has been approved by the Institutional Review Board of the Hospital Ramón y Cajal in Madrid. We will present our findings at national and international congresses, and peer-reviewed journals.Trial Registration number NCT05858099.https://bmjopen.bmj.com/content/13/9/e072455.full |
| spellingShingle | Leticia Fernandez-Friera Jorge Solis Joel M Gelfand Carlota Abbad-Jaime de Aragón Emilio Berna-Rico María Asunción Ballester-Martinez Pedro Jaén Nehal N Mehta Álvaro González-Cantero María G Barderas Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study BMJ Open |
| title | Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study |
| title_full | Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study |
| title_fullStr | Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study |
| title_full_unstemmed | Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study |
| title_short | Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study |
| title_sort | early detection and progression of subclinical atherosclerosis in psoriasis edsap protocol for an observational single centre prospective cohort study |
| url | https://bmjopen.bmj.com/content/13/9/e072455.full |
| work_keys_str_mv | AT leticiafernandezfriera earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT jorgesolis earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT joelmgelfand earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT carlotaabbadjaimedearagon earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT emiliobernarico earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT mariaasuncionballestermartinez earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT pedrojaen earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT nehalnmehta earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT alvarogonzalezcantero earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy AT mariagbarderas earlydetectionandprogressionofsubclinicalatherosclerosisinpsoriasisedsapprotocolforanobservationalsinglecentreprospectivecohortstudy |